Recurring concern
Failure to provide timely treatment for constipation and impacted faeces
First reported 22 Aug 2014•Latest report 12 Aug 2025
What this concern includes
Includes failures in the treatment process for clinically significant constipation or impacted faeces, including timely prescribing, administration, monitoring and escalation of indicated enemas, laxatives or comparable treatment.
Not included
- Excludes bowel-monitoring or documentation failures when required constipation treatment itself was provided reliably.
- Excludes generic delays in clinical treatment where constipation or impacted faeces is not the identified condition.
- Excludes unrelated bowel conditions or treatment failures without a material constipation or faecal-impaction component.
- Excludes failures occurring after appropriate constipation treatment has been provided when the remaining concern is solely follow-up or another downstream process.
- Reports
- 3
- Individual concerns
- 3
- Date range
- 2014–2025
- Stated actions
- 3
Distinct published reports
A report can raise multiple concerns
First to latest report issue date
Described in published responses
Reports over time
Reports over time
Reports about this concern issued each year.
* 2026 is projected from reports observed to 7 Sep 2026.
Most frequent recipients
Most frequent recipients
Reports about this concern sent to each recipient.
Concerns and responses across reports
Only concerns grouped under this recurring concern are included. Select any concern, action or position to view the source wording.
-
Concerns raised1
Delays in managing clozapine constipation
This report raised 7 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.2
-
Action
Disseminate the January 2025 updated clozapine policy across medical teams to strengthen constipation assessment, monitoring and documentation.
Stated by Essex Partnership University NHS Foundation Trust -
Action
Deliver dedicated teaching on monitoring and documenting clozapine side effects.
Stated by Essex Partnership University NHS Foundation Trust
-
Concerns raised1
Failure to account for respiratory compromise when administering laxatives
This report raised 4 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.1
-
Action
Remind medication prescribers to select, dispense and administer medicines correctly under NICE and BNF guidance, reinforcing safe maximum-dose awareness and pharmacist dosage scrutiny.
Stated by Swansea Bay University Local Health Board
-
Concerns raised1
Failure to prescribe and administer treatment for impacted faeces and constipation
This report raised 8 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
No linked response statementsNo respondent-stated action or position is linked to these concerns in the published data.
Data last updated 7 September 2026